• Enesi Pharma appoints Elizabeth Eagling-Vose, MBA, as Senior Vice President, Operations

  7th September 2021

  Experienced leader in clinical operations joins Enesi to drive the development of vaccine programmes enabled using its innovative ImplaVax® solid dose, needle-free technology Oxford, UK, 7 September 2021 – Enesi Pharma Ltd (“Enesi”), an innovative biotechnology company developing next-generation vaccination products, targeting infectious diseases and emergent threat pathogens, enabled by its world leading ImplaVax® technologies,… read more

• Enesi Pharma’s ImplaVax^® Technology Platform Spotlighted in Medical Device Developments Article on Elimination of Cold Chain Logistics

  22nd June 2021

  OXFORD, UK – 22 June 2021 – Enesi Pharma is pleased to acknowledge Lynette Eyb’s excellent article ‘A Total Meltdown’ in Medical Device Developments’  where the potential of Enesi’s proprietary ImplaVax® formulation and delivery technologies are discussed. The Article ‘A Total Meltdown‘ highlights how next generation vaccination technologies such as ImplaVax® needle-free, thermally stable unit… read more

• Enesi Pharma’s ImplaVax^®-Enabled, Solid-Dose Recombinant Classical Swine Fever (CSF) Vaccine Produces Immune Responses Superior to Liquid Vaccine

  6th May 2021

  Second positive study in important animal health indications using different vaccine constructs demonstrates potential of ImplaVax®-enabled needle-free thermally stable solid-dose vaccination platform with read-through to human health OXFORD, UK – 6 May 2021 – Enesi Pharma (“Enesi”), an innovative biotechnology company developing next-generation vaccination products targeting infectious diseases and emergent threat pathogens enabled by its… read more

• Enesi Pharma Achieves Key Milestone in Development of Thermostable Solid-dose Live Vaccines against Measles and Rubella

  5th May 2021

  OXFORD, UK – 5 May 2021 – Enesi Pharma (“Enesi”), an innovative biotechnology company developing next-generation vaccination products targeting infectious diseases and emergent threat pathogens enabled by its ImplaVax® technologies, announces it has achieved a key milestone in its project to develop needle-free thermostable unit solid-dose live vaccines with retained activity against Measles and Rubella…. read more

• Enesi Pharma Achieves Preclinical Proof-of-Concept with ImplaVax®-Enabled Pandemic Influenza Vaccine

  4th May 2021

  Innovative needle-free injectable unit solid-dose presentation of recombinant H7N9 pandemic flu vaccine, created using Enesi’s ImplaVax® technology, generated immune responses comparable with liquid vaccine and demonstrated excellent thermal stability at temperatures up to 40°C for six months.   OXFORD, UK – 4 May 2021 – Enesi Pharma (“Enesi”), an innovative biotechnology company developing next-generation vaccination… read more

• Enesi Pharma to Present at World Vaccine Congress 2021 Virtual Meeting

  26th April 2021

  OXFORD, UK – 26 April 2021 – Enesi Pharma (“Enesi”), an innovative biotechnology company developing next-generation vaccination products targeting infectious diseases and emergent threat pathogens enabled by its ImplaVax® technologies, announces that its CEO, David Hipkiss will give a presentation at the upcoming World Vaccine Congress 2021 Virtual meeting (4-6 May 2021), which this year… read more

• Enesi Pharma’s ImplaVax^® Solid-Dose Needle-free Vaccination Technology Featured in the Wall Street Journal

  5th March 2021

  Enesi Pharma’s CEO, David Hipkiss, spoke to WSJ reporter Jason Douglas about Enesi’s ImplaVax® solid-dose needle-free vaccination technology as part of a larger feature investigating how the COVID-19 pandemic has spurred innovation into new vaccination technologies that use alternative approaches to traditional needle and syringe delivery. The story, published on 3rd March 2021, can be… read more

• Enesi Pharma ImplaVax^® Solid Dose Needle-free Vaccination Technology Featured on Leading News Channel in Japan

  19th February 2021

  Enesi Pharma recently hosted a crew from Asahi TV, one of Japan’s leading TV channels, at its Oxford, UK facility to talk about the potential of its ImplaVax® solid dose needle-free vaccination technology. The conversation coincided with the approval of the Pfizer/BioNTech COVID-19 vaccine Comirnaty® in Japan and potential dose-wasting issues linked to the type… read more

• Enesi Pharma and Imperial College London Collaborate to Develop Thermostable RNA Vaccines with Potential to Eliminate Cold Chain and Transform Global Vaccination Logistics for COVID-19

  18th December 2020

  OXFORD and LONDON, UK – 18 December 2020 – Enesi Pharma (“Enesi”), an innovative biotechnology company developing next-generation vaccination products targeting infectious diseases and emergent threat pathogens enabled by its ImplaVax® technologies, announces it is collaborating with Prof. Robin Shattock, a leading infectious disease and vaccine expert, and his group at Imperial College London (“Imperial”),… read more

• Enesi Pharma’s ImplaVax^® Solid-Dose and Needle-Free Vaccination Platform Wins Best New Vaccine Technology/ Platform Award at the World Vaccine Congress

  1st October 2020

  OXFORD, UK – 1 October 2020 – Enesi Pharma (“Enesi”), an innovative biotechnology company developing next-generation vaccination products targeting infectious diseases and emergent threat pathogens enabled by its ImplaVax® technologies, is delighted to announce that ImplaVax® has won the ‘Best New Vaccine Technology/Platform Award’ at the World Vaccine Congress Washington Virtual annual event (28 September… read more

• Enesi Pharma’s ImplaVax^®-Enabled, Solid-Dose Modified Live Virus Vaccine Produces Neutralising Antibody and T-Cell Responses Equivalent to Liquid Vaccine Delivered via Needle and Syringe

  29th September 2020

  Study investigating potential of solid-dose vaccine for porcine reproductive and respiratory syndrome virus (PRRSV) conducted in collaboration with The Pirbright Institute Positive top-line results demonstrate validation of ImplaVax®-enabled solid-dose vaccination approach with a live virus vaccine OXFORD, UK – 29 September 2020 – Enesi Pharma (“Enesi”), an innovative biotechnology company developing next-generation vaccination products targeting… read more

• Enesi Pharma Appoints Vaccine Development Expert Dr Keith Howard as Chief Scientific Officer to Lead Research & Development of Novel ImplaVax^® Solid-dose, Needle-free Vaccination Products

  28th September 2020

  OXFORD, UK – 28 September 2020 – Enesi Pharma (“Enesi”), an innovative biotechnology company developing next-generation vaccination products targeting infectious diseases and emergent threat pathogens enabled by its world leading ImplaVax® technologies, is delighted to announce the appointment of Keith Howard as Chief Scientific Officer. Dr Howard is a seasoned vaccine development expert who will… read more

• Enesi Pharma’s ImplaVax^® platform shortlisted in the Best Emerging Medtech Company Category at the OBN Awards 2020

  9th September 2020

  OXFORD, UK – 9 September 2020 – Enesi Pharma announces that its proprietary ImplaVax® solid dose, needle-free device and formulation technology has been shortlisted as an OBN Awards finalist in the Best Emerging Medtech Company Category recognising the potential of our unique ImplaVax® needle free, thermally stable, immune enhancing unit solid dose vaccination technology platform… read more

• Enesi Pharma to Develop Thermostable Solid Dose DNA Vaccine Targeting Zika Virus under New Partnership with The University of Adelaide

  3rd September 2020

  OXFORD, UK – 03 September 2020 – Enesi Pharma (“Enesi”), an innovative biotechnology company developing next-generation vaccination products targeting serious diseases, is delighted to announce its partnership with the University of Adelaide to develop a new thermostable, solid dose DNA vaccine for Zika virus to prevent infection of pregnant women and the resultant congenital effects… read more

• Enesi Pharma to participate at BIO International Convention Digital

  4th June 2020

  Enesi Pharma, an innovative pharmaceutical company developing unique injectable solid dose drug-device vaccine products, will participate at the BIO International Convention Digital (BIO Digital), taking place on 8th – 12th June 2020. Meet us using the BioPartnering Platform to learn how we are using our ImplaVax® formulation and device technology to develop a range of… read more

• Enesi Pharma’s ImplaVax^® platform shortlisted for Best New Vaccine Technology/Platform at the Vaccine Industry Excellence (ViE) Awards 2020

  2nd March 2020

  OXFORD, UK – 02 Mar 2020 – Enesi Pharma announces that its proprietary ImplaVax® solid dose, needle-free device and formulation technology has been shortlisted as a finalist for the Best New Vaccine Technology/Platform Award, the winner of which will be revealed at the 13th Annual Vaccine Industry Excellence (ViE) Awards ceremony and gala dinner on… read more

• Enesi Pharma’s ImplaVax® platform nominated for Best New Vaccine Technology/Platform at the Vaccine Industry Excellence (ViE) Awards 2020

  4th February 2020

  OXFORD, UK – 4 February 2020 – Enesi Pharma announces that its proprietary ImplaVax® solid dose, needle-free device and formulation technology has been nominated in the Best New Vaccine Technology/Platform category, at the 13th Annual Vaccine Industry Excellence (ViE) Awards. The ViE Awards honour and recognize the efforts, accomplishments, and positive contributions of companies and… read more

• Enesi Pharma Presenting at the BIO CEO & Investor Conference, New York

  31st January 2020

  OXFORD, UK – 31 January 2020 – Enesi Pharma (“Enesi”), the innovative pharmaceutical company developing unique needle-free, unit solid dose vaccines, is attending and presenting at the upcoming BIO CEO & Investor Conference in New York, USA taking place from 10th – 11th February 2020. David Hipkiss, CEO, will be presenting Enesi’s innovative ImplaVax® platform… read more

• Enesi Pharma Awarded Grant Funding to Develop and Evaluate ImplaVax^® enabled Solid Dose Vaccines Targeting Measles and Rubella Grant funding provided by the Bill & Melinda Gates Foundation

  29th October 2019

  OXFORD, UK – 29 October 2019 – Enesi Pharma (“Enesi”), the innovative pharmaceutical company developing unique injectable solid dose drug-device vaccine products, is delighted to announce that it has been awarded grant funding from the Bill & Melinda Gates Foundation. The funding will support a new project to evaluate Enesi’s ImplaVax® technology platform for enabling… read more

• Enesi Pharma to participate at the World Vaccine Congress Europe from 29^th – 31^st October 2019

  22nd October 2019

  OXFORD, UK – 22nd October 2019 – Enesi Pharma (“Enesi”), the innovative pharmaceutical company developing unique injectable solid dose drug-device vaccine products, announces it is participating at the upcoming World Vaccine Congress Europe 2019 in Barcelona, Spain (29th – 31st October 2019). Enesi is a Silver Sponsor of the event and will also showcase its… read more

• Enesi Pharma Secures Innovate UK Funding to Enable Scalable Aseptic Manufacturing of ImplaVax^® enabled Solid Dose Viral Vector Vaccines

  24th September 2019

  OXFORD, UK – 24 September 2019 – Enesi Pharma (“Enesi”), the innovative pharmaceutical company developing unique injectable solid dose drug-device vaccine products, is delighted to announce that it has secured substantial funding from Innovate UK, the UK’s innovation agency, under the Biomedical Catalyst 2019 Round 1: Early and Late Stage Awards Initiative. The award of… read more

• Enesi Pharma adds Global Vaccine and Infectious Disease Expert Steven Chatfield to its Scientific Advisory Board

  1st July 2019

  Oxford, UK – 1 July 2019. Enesi Pharma, the innovative pharmaceutical company developing unique injectable solid dose vaccine products, announces the appointment of Dr Steven Chatfield to its Scientific Advisory Board (SAB). Dr Chatfield is an internationally recognised vaccine and infectious disease expert and brings nearly 40 years’ experience in R&D, executive, board and advisory… read more

• Enesi Pharma and BARDA Drive enter Public-Private Partnership to Develop ImplaVax^® Solid Dose Vaccine Delivery Technology against Influenza

  15th April 2019

  OXFORD, UK – 15 April 2019 – Enesi Pharma (“Enesi”), an innovative pharmaceutical company developing unique injectable solid dose drug-device vaccine products, announces it has entered a public-private partnership with the U.S. Biomedical Advanced Research and Development Authority’s (BARDA) DRIVe (Division of Research, Innovation, and Ventures) initiative to develop new vaccines against influenza enabled by… read more

• Enesi Pharma’s ImplaVax^® platform shortlisted for Best New Vaccine Technology/Platform at the Vaccine Industry Excellence (ViE) Awards 2019

  10th April 2019

  OXFORD, UK – 10 April 2019 – Enesi Pharma announces that its proprietary ImplaVax® solid dose, needle-free device and formulation technology has been shortlisted for the Best New Vaccine Technology/Platform Award, the winner of which will be revealed at the 12th Annual Vaccine Industry Excellence (ViE) Awards 2019 ceremony and gala dinner on 15 April…. read more

• Enesi Pharma to participate at World Vaccine Congress 2019 in Washington DC

  10th April 2019

  OXFORD, UK – 10 April 2019 – Enesi Pharma, an innovative pharmaceutical company developing unique injectable solid dose drug-device vaccine products, will participate at the World Vaccine Congress, taking place on 14-17 April in Washington, DC. The Company will showcase its ImplaVax® solid dose, needle-free device and formulation technology for the development of novel vaccine… read more

• Enesi Pharma and University of Oxford collaborate to target plague with a novel ImplaVax^®-enabled adenovirus-based solid dose vaccine

  9th April 2019

  OXFORD, UK – 09 April 2019 – Enesi Pharma (“Enesi”), an innovative pharmaceutical company developing unique injectable solid dose drug-device vaccine products and scientists at the world-renowned Oxford Vaccine Group (“OVG”) at the University of Oxford, announce they have entered into a collaborative agreement to create and test a solid dose vaccine against plague. The… read more

• Enesi Pharma and GeoVax to Collaborate on Development of Multiple Vaccines Administered by ImplaVax® a Novel Needle-Free Vaccine Delivery Platform

  2nd January 2019

  Potential for Addressing Multiple Infectious Disease Targets OXFORD, UK and ATLANTA, GA – 2 January 2019 – Enesi Pharma, an innovative pharmaceutical company developing unique injectable solid dose drug-device vaccine products, and GeoVax Labs, Inc. (OTCQB: GOVX), a biotechnology company developing human vaccines, announced today a collaboration to develop solid-dose needle-free vaccine formulations utilizing GeoVax’s… read more

• Enesi Pharma and Sementis sign R&D Collaboration focused on Needle-free Solid Dose Vaccines for Peanut Allergy and chikungunya/Zika Infection

  5th November 2018

  Oxford, UK and Melbourne, Australia – 5 November 2018. Enesi Pharma, an innovative pharmaceutical company developing unique injectable solid dose drug-device vaccine products, and Sementis, a biotechnology company developing innovative vaccine candidates for the prevention of allergies and infectious diseases, announce they have entered into a collaborative agreement. The collaboration is focused on the development… read more

• Enesi Pharma Selected to Showcase Unique ImplaVax® Needle-Free Solid Dose Vaccine Platform in Inaugural ‘Lightning Talk’ Session at BARDA Industry Day

  16th October 2018

  Oxford, UK – 16 October 2018. Enesi Pharma, an innovative pharmaceutical company developing unique injectable solid dose vaccine products, is honoured to have been selected to present a ‘Lightning Talk’ at The Biomedical Advanced Research and Development Authority (BARDA) Industry Day on 29-30 October at the Grand Hyatt in Washington DC, U.S.   BARDA is a key… read more

• Enesi Pharma to showcase unique ImplaVax® Needle-Free Solid Dose Vaccine Platform at World Vaccine Congress Europe 2018

  4th October 2018

  Oxford, UK – 4 October 2018. Enesi Pharma, an innovative pharmaceutical company developing unique injectable solid dose drug-device vaccine products, announces it will showcase its innovative ImplaVax® needle-free solid dose vaccine platform at the upcoming World Vaccine Congress Europe 2018 in Lisbon, Portugal (29-31 October 2018). Enesi Pharma is once again a Silver Sponsor of… read more

• Enesi Pharma and Public Health England Enter R&D Collaboration for Novel Needle-Free Solid-Dose Vaccine for Emergent Threat Pathogens

  1st October 2018

  Oxford, UK – 1st October 2018. Enesi Pharma, an innovative pharmaceutical company developing unique injectable solid dose vaccine products, announces it has entered a research and development collaboration with Public Health England (PHE), an executive agency of the UK Government’s Department of Health and Social Care.  The collaboration is focused on the development and evaluation… read more

• Enesi Pharma and Walter Reed Army Institute of Research (WRAIR) sign Cooperative R&D Agreement (CRADA) for Needle-Free Solid-Dose Vaccine for Shigella Infection

  24th September 2018

  Oxford, UK – 24th September 2018. Enesi Pharma, an innovative pharmaceutical company developing unique injectable solid dose vaccine products, announces it has entered a Cooperative Research and Development Agreement (CRADA) with the Walter Reed Army Institute of Research (WRAIR), a United States Department of Defense Laboratory, regarding Shigella vaccine development. The CRADA is focused on… read more

• Enesi Pharma Drives Forward Growth Plans with Move to New State-Of-The-Art Headquarters in Oxford

  20th September 2018

  Oxford, UK – 20th September 2018. Enesi Pharma, an innovative pharmaceutical company developing unique injectable solid dose drug-device vaccine products, is delighted to announce the opening of its new headquarters including state-of-the-art research and development facilities in Milton Park, Oxford, in the heart of the UK’s dynamic life science cluster.  Since its launch in 2017… read more

• Enesi Pharma Welcomes Global Vaccine Expert James Cheyne to its Scientific Advisory Board

  3rd September 2018

  Oxford, UK – 3 September 2018. Enesi Pharma, an innovative pharmaceutical company developing unique injectable solid dose vaccine products, announces the appointment of James Cheyne to its Scientific Advisory Board (SAB). Enesi’s SAB comprises experts in vaccines and preventative health from leading academic, research and international health organisations across the US and Europe. Mr Cheyne… read more

• Enesi Pharma presenting at the World Vaccine Congress, Washington – Wednesday 4 April 2018

  29th March 2018

  Enesi Pharma are attending the World Vaccine Congress, Washington 3-5 April 2018. David Hipkiss, CEO, will be presenting  our latest developments in the Viral Vectors & Novel Platforms Technology Showcase entitled ImplaVaxTM , Unique needle free solid dose vaccine platform delivering enhanced immunogenicity with ultimate convenience and no cold chain at 10.25am on Wednesday, in Ballroom level… read more

• Enesi Pharma appoints new international Scientific Advisory Board

  6th November 2017

  Oxford, UK – 6 November 2017. Enesi Pharma, a clinical-stage company developing unique injectable solid dose drug-device combination products, announces the formation of a new International Scientific Advisory Board (SAB). The SAB includes experts in vaccines and preventative health from leading academic/ research and international health organisations in the US and Europe. Commenting on the… read more

• Enesi Pharma debuts at World Vaccine Congress

  5th October 2017

  Oxford, UK – 10 October 2017. Enesi Pharma, a clinical-stage company developing unique injectable solid dose drug-device combination products, announces its launch as a new company at the World Vaccine Congress, which takes place on 10-12 October in Barcelona, Spain. Enesi is focused on the development of innovative vaccines and therapeutics using its proprietary ImplaVax™… read more